Mr. Peikwen Cheng is Co-founder and CEO of Yiviva, a biotechnology start-up that develops first-in-class therapeutics. The company developed YIV906, an herbal mixture based on an 1,800-year-old Chinese formula. A number of clinical studies show YIV906 reduces the harmful adverse…
By Sujuan Ba, Ph.D. In 1975 the United Nations General Assembly designated March 8 as International Women's Day. While the original focus was about celebrating the economic, political, and social achievements of women, to many this has become simply an…
ROCKVILLE, MD & BOSTON, MA – An AIM-HI Accelerator Fund portfolio company exclusively focused on the development of pediatric cancer therapeutics has garnered recognition and additional funding. Oncoheroes Biosciences Inc. won the Squinto-LePera Award at the Lyfebulb-Helsinn Cancer Innovation Summit…
More than 20 years ago, Yale pharmacology professor Yung-Chi Cheng, a leader in drug development for hepatitis B, cancer, and HIV, had a radical idea: What if he could unlock the therapeutic potential of ancient Chinese medicines for treating cancer?…
A drug and drug delivery candidate technology, research into which has been funded by the National Foundation for Cancer Research (NFCR), has recently been approved by the U.S. Food and Drug Administration (FDA) for the initiation of human clinical trials.…
First of Its Kind Investment Competition for Female-Led Cancer-Focused Start-Ups ROCKVILLE, MD – The AIM-HI Accelerator Fund is organizing the first annual Women’s Venture Competition on May 20 in Boston. Applications are being accepted online until April 16 from oncology…
ROCKVILLE, MD – The co-founder and CEO of the AIM-HI Accelerator Fund will chair a panel conversation at an event coinciding with the annual JP Morgan Healthcare Conference. On Sunday, January 12, Sujuan Ba, Ph.D., will lead a morning discussion…
ROCKVILLE, MD – A portfolio start-up company of the AIM-HI Accelerator Fund has been awarded $700,000 from Virginia Catalyst to commercialize its lead cancer drug candidate. Richmond-based InterLeukin Combinatorial Therapies (ILCT) is developing unique engineered therapeutic interleukins (a type of…
By Franklin C. Salisbury, Jr. The National Foundation for Cancer Research funds “high risk|high reward” research with a singular focus on one absolute and immutable goal: research to cure cancer – cures for all types of cancer. Since 1973 with…
